Filing Flows › Rani Therapeutics Holdings (RANI) › Q2 2026
Rani Therapeutics Holdings (RANI) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the second quarter 2026 (Q2 2026) and 0% from the quarter before. Operating margin was -516.9%, net loss $8.4M (493.0% of revenue).
Rani Therapeutics Holdings, Q2 2026: revenue $1.7M, operating margin -516.9%, net loss $8.4M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | 0% | — |
| Operating profit | −$8.8M | — | — |
| Net earnings | −$8.4M | — | — |
| Operating cash flow | −$9.0M | — | — |
What changed
Revenue was $1.7M in Q2 2026, roughly flat from the previous quarter.
Operating costs exceeded revenue by $8.8M, an operating margin of -516.9%. The quarter ended with a net loss of $8.4M, wider than the previous quarter's $8.0M loss. Minority interests bore $1.0M of it: to shareholders the quarter was a loss of $7.4M.
Operating cash flow was −$9.0M. Non-cash charges added back $152K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $3.2M. Capital expenditures of $32K exceeded it, leaving free cash flow of −$9.1M.
Questions
What was Rani Therapeutics Holdings' revenue in the second quarter 2026?
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the second quarter 2026 (Q2 2026) and 0% from the quarter before.
Was Rani Therapeutics Holdings profitable in the second quarter 2026?
Operating loss was $8.8M (-516.9% of revenue) and net loss $8.4M.